{{Rsnum
|rsid=4791171
|Gene=AXIN2
|Chromosome=17
|position=65545379
|Orientation=minus
|GMAF=0.4555
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=AXIN2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 14.2 | 40.7 | 45.1
| HCB | 44.5 | 43.1 | 12.4
| JPT | 49.6 | 39.8 | 10.6
| YRI | 72.8 | 25.2 | 2.0
| ASW | 54.4 | 40.4 | 5.3
| CHB | 44.5 | 43.1 | 12.4
| CHD | 50.5 | 39.4 | 10.1
| GIH | 13.9 | 48.5 | 37.6
| LWK | 64.5 | 35.5 | 0.0
| MEX | 8.6 | 60.3 | 31.0
| MKK | 50.0 | 38.3 | 11.7
| TSI | 13.7 | 44.1 | 42.2
| HapMapRevision=28
}}{{PMID|18708403|OA=1
}} 798 invasive [[breast cancer]] cases and 843 unaffected controls. [[rs4791171]] associated with risk in premenopausal (P(trend) = 0.0002) but not in postmenopausal women

{{PharmGKB
|RSID=rs4791171
|Name_s=
|Gene_s=AXIN2
|Feature=
|Evidence=PubMed ID:18708403
|Annotation=In 798 invasive breast cancer cases and 843 unaffected controls this SNP in the AXIN2 gene was significantly associated with risk in premenopausal but not in postmenopausal women.
|Drugs=
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA162191344
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4791171
|overall_frequency_n=63
|overall_frequency_d=126
|overall_frequency=0.5
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=48
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Affy500k}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}